Pro MedicusASX:PME +3.50%98 FCF Margin % is 52.07% as of Dec. 2025, which is 21% above its 10-year median of 43.21. GuruFocus rates ASX:PME with a GF Score™ of 98/100 and a GF Value™ of A$244.83 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 669 Healthcare Providers & Services companies, Pro Medicus ranks better than 98.65% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pro Medicus's Free Cash Flow for the
six
months ended in Dec. 2025 was A$65.0 Mil. Pro Medicus's Revenue for the
six
months ended in Dec. 2025 was A$124.7 Mil. Therefore, Pro Medicus's FCF Margin % for the quarter that ended in Dec. 2025 was 52.07%.
The historical rank and industry rank for Pro Medicus's FCF Margin % or its related term are showing as below:
ASX:PME'
s FCF Margin % Range Over the Past 10 Years
Min: 3.69 Med: 43.21 Max: 56.27
Current: 50.08
During the past 13 years, the highest FCF Margin % of Pro Medicus was 56.27%. The lowest was 3.69%. And the median was 43.21%.
ASX:PME's FCF Margin % is ranked better than 98.65% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 3.34
vs ASX:PME: 50.08
Pro Medicus FCF Margin % Related Terms
Pro Medicus FCF Margin % Historical Data
* Premium members only.
The historical data trend for Pro Medicus's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PME vs VEEV, BTSG, TEM: FCF Margin % Comparison
For the Health Information Services subindustry, Pro Medicus's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Pro Medicus's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro Medicus (ASX:PME) has a FCF Margin % of 52.07% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pro Medicus and its competitors. This is 21% above median its historical median of 43.21. Over the past decade, Pro Medicus' FCF Margin % has ranged from 3.69 to 56.27. According to the industry distribution chart, Pro Medicus ranks #9 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 1.3%.
Is Pro Medicus' FCF Margin % too high?
Pro Medicus' current FCF Margin % of 52.07% is 21% above median its 10-year median of 43.21. Over the past 10 years, this metric has ranged from a low of 3.69 to a high of 56.27. The Healthcare Providers & Services industry median FCF Margin % is 3.34. Pro Medicus' value of 52.07% is 1459% above this industry median. Based on the distribution chart, Pro Medicus ranks #9 out of 669 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pro Medicus has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' FCF Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #9 out of 669 companies for FCF Margin %. This places Pro Medicus in the top 1% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.34. Pro Medicus' value of 52.07% is 1459% above this benchmark. Historically, Pro Medicus' own FCF Margin % has ranged from 3.69 to 56.27 over the past decade. While the company's 10-year median is 43.21 vs. the industry median of 3.34, Pro Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.34, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current FCF Margin % of 52.07% is 1459% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pro Medicus and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current FCF Margin % is 52.07%, which is 21% above median its own 10-year median of 43.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (ASX:PME) is currently considered Modestly Undervalued. The stock's GF Value™ is A$244.83, compared to a current price of A$178.99 — trading 26.9% below its estimated fair value. The current FCF Margin % is 52.07%, which is 21% above median its 10-year median of 43.21 and 1459% above the Healthcare Providers & Services industry median of 3.34. Pro Medicus' overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pro Medicus (ASX:PME), the current FCF Margin % is 52.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (ASX:PME) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of A$178.99 is trading 26.9% below its estimated GF Value™ of A$244.83.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for ASX:PME:
FCF Margin %: 52.07% (21% above median its 10-year median of 43.21)
GF Value™: A$244.83 vs. price of A$178.99 (26.9% below fair value)
Industry Position: 1459% above the Healthcare Providers & Services median (#9 of 669)
No single metric tells the full story. See the ASX:PME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
98GF Score
Get the complete analysis for ASX:PME
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PME has been successfully added to your 
